Surya K. De* Pages 791 - 795 ( 5 )
Elacestrant was approved by the US FDA on January 27, 2023, for treating postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2- negative, ESR1-mutated advanced or metastatic breast cancer with disease progression prior to using at least one line of endocrine therapy. In this short perspective, physicochemical properties, dosage and administration, mechanism of action, pharmacodynamics, pharmacokinetics, drug interaction, and treatment-related adverse reactions of elacestrant are summarized.
Selective estrogen receptor degraders, elacestrant, giredestrant, fulvestrant tamoxifen, endocrine therapy, estrogen receptor 1 gene.